pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Litfulo
drug
save

ritlecitinib

Marketedupdated 3mo ago
by $PFE PFIZER INC
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ritlecitinib

  • —Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the UScompletedn=300
  • phase2A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.recruitingn=240
  • phase2A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.recruitingn=200
  • —A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settingscompletedn=123
  • —Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinibrecruitingn=850
  • phase2Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)active not recruitingn=78
  • —A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.recruitingn=3,000
  • phase3A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areataactive not recruitingn=550
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Jun 23, 2028
~1.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

  • Oct 17, 2041compositionUS 12116368
  • Dec 3, 2034method-of-use (U-3994)US 12077533
  • Dec 3, 2034compositionUS 9617258

FDA exclusivities (1)

  • Jun 23, 2028NCENew Chemical Entity (5y)1.9y

News(2)

  • Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
    Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
    biopharma_dive · 11d ago
  • Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M
    Pfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune condition that causes skin to progressively lose its color. One ...
    endpoints · 12d ago
brand
Litfulo
generic
ritlecitinib [INN]
indication
Alopecia Areata
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 30m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?